litlas
Log inCreate account

Amy J. Johnson

Active 1978–2025

73
Papers
18,930
Citations
59
h-index
71
i10-index

Citations

Citations per year for Amy J. Johnson1978: 1 citations1979: 4 citations1980: 1 citations1981: 4 citations1982: 2 citations1983: 3 citations1984: 1 citations1985: 3 citations1986: 2 citations1987: 3 citations1989: 3 citations1990: 2 citations1991: 1 citations1995: 1 citations1999: 1 citations2000: 1 citations2001: 1 citations2002: 4 citations2003: 3 citations2004: 9 citations2005: 9 citations2006: 8 citations2007: 14 citations2008: 28 citations2009: 63 citations2010: 66 citations2011: 87 citations2012: 119 citations2013: 186 citations2014: 288 citations2015: 386 citations2016: 319 citations2017: 326 citations2018: 330 citations2019: 938 citations2020: 879 citations2021: 947 citations2022: 523 citations2023: 360 citations2024: 526 citations2025: 236 citations2026: 11 citations1988: no citations, so this year is not shown1992–1994: no citations, so these years are not shown1996–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,002 citing papers, 30.1% of this breakdownChina: 575 citing papers, 8.6% of this breakdownUnited Kingdom: 490 citing papers, 7.4% of this breakdownGermany: 427 citing papers, 6.4% of this breakdownItaly: 375 citing papers, 5.6% of this breakdownFrance: 266 citing papers, 4% of this breakdownSpain: 225 citing papers, 3.4% of this breakdownAustralia: 223 citing papers, 3.4% of this breakdownCanada: 204 citing papers, 3.1% of this breakdownNetherlands: 152 citing papers, 2.3% of this breakdownSwitzerland: 148 citing papers, 2.2% of this breakdownSweden: 116 citing papers, 1.7% of this breakdown
0%30.1%Other 21.8%

Institutions

Fields

  • Medicine64.8%
  • Biochemistry, Genetics and Molecular Biology26.9%
  • Immunology and Microbiology4%
  • Chemistry1.7%
  • Neuroscience0.7%
  • Computer Science0.6%
  • Other1.3%

Topics

  • Chronic Lymphocytic Leukemia Research15.2%
  • Lymphoma Diagnosis and Treatment10%
  • CAR-T cell therapy research4.5%
  • Protein Degradation and Inhibitors3.9%
  • Immunodeficiency and Autoimmune Disorders3.6%
  • Chronic Myeloid Leukemia Treatments3%
  • Other59.8%

Coauthors

All papers

Open in search
  1. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

    Authors: Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gülçin Özer, Marc Zapatka, Amy S. Ruppert, Ling Xue, Daniel Hsieh-Hsin Li, Susanne Steggerda, Matthias Versele, Sandeep S. Davé, Jenny Zhang, Ayse Selen Yilmaz, Samantha Jaglowski, Kristie A. Blum, Arletta Lozanski, Gerard Lozanski, Danelle F. James, Jacqueline C. Barrientos, Peter Lichter, Stephan Stilgenbauer, Joseph J. Buggy, Betty Chang, Amy J. Johnson, John C. Byrd - New England Journal of Medicine 2014 cited by 1,254

  2. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation

    Authors: Alexandru D. Buhimschi, Haley A. Armstrong, Momar Toure, Saul Jaime‐Figueroa, Timothy L. Chen, Amy M. Lehman, Jennifer A. Woyach, Amy J. Johnson, John C. Byrd, Craig M. Crews - Biochemistry 2018 cited by 372

  3. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    Authors: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien - New England Journal of Medicine 2013 cited by 2,249

  4. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

    Authors: Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn, Amy Lehman, James S. Blachly, Arletta Lozanski, Nyla A. Heerema, Weiqiang Zhao, Joshua F. Coleman, Daniel Jones, Lynne V. Abruzzo, Amber Gordon, Rose Mantel, Lisa L. Smith, Samantha McWhorter, Melanie E. Davis, Tzyy-Jye Doong, Fan Ny, Margaret S. Lucas, Weihong Chase, Jeffrey A. Jones, Joseph M. Flynn, Kami J. Maddocks, Kerry A. Rogers, Samantha Jaglowski, Leslie A. Andritsos, Farrukh T. Awan, Kristie A. Blum, Michael R. Grever, Gerard Lozanski, Amy J. Johnson, John C. Byrd - Journal of Clinical Oncology 2017 cited by 471

  5. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    Authors: John C. Byrd, Bonnie K. Harrington, Susan O’Brien, Jeffrey A. Jones, Anna Schuh, Steve Devereux, Jorge Chaves, William G. Wierda, Farrukh T. Awan, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer A. Woyach, Dave Johnson, Jane Huang, Xiaolin Wang, Allard Kaptein, Brian J. Lannutti, Todd Covey, Maria Fardis, Jesse McGreivy, Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Thomas G. Diacovo, Amy J. Johnson, Richard R. Furman - New England Journal of Medicine 2015 cited by 891

  6. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

    Authors: Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua Hessler, Ta-Ming Liu, Betty Chang, Karilyn M. Larkin, Matthew Stefanovski, Danielle L. Chappell, Frank Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami J. Maddocks, Amy M. Lehman, Richard R. Furman, Jeff P. Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd - Blood 2013 cited by 796

  7. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

    Authors: Sarah E. M. Herman, Amber Gordon, Erin Hertlein, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski, Joseph M. Flynn, Jeffrey J. Jones, Kristie A. Blum, Joseph J. Buggy, Ahmed Hamdy, Amy J. Johnson, John C. Byrd - Blood 2011 cited by 791

  8. DNA Origami Nanostructures Elicit Dose‐Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo

    Authors: Christopher R. Lucas, Patrick D. Halley, Amjad A. Chowdury, Bonnie K. Harrington, Larry Beaver, Rosa Lapalombella, Amy J. Johnson, Erin Hertlein, Mitch A. Phelps, John C. Byrd, Carlos E. Castro - Small 2022 cited by 103

  9. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

    Authors: Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski, Nyla A. Heerema, Weiqiang Zhao, Lynne V. Abruzzo, Arletta Lozanski, Melanie E. Davis, Amber Gordon, Lisa L. Smith, Rose Mantel, Jeffrey A. Jones, Joseph M. Flynn, Samantha Jaglowski, Leslie A. Andritsos, Farrukh T. Awan, Kristie A. Blum, Michael R. Grever, Amy J. Johnson, John C. Byrd, Jennifer A. Woyach - JAMA Oncology 2015 cited by 576

  10. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

    Authors: Joseph A. Fraietta, Kyle A. Beckwith, Prachi Patel, Marco Ruella, Zhaohui Zheng, David M. Barrett, Simon F. Lacey, J. Joseph Melenhorst, Shannon E. McGettigan, Danielle Cook, Changfeng Zhang, Jun Xu, Priscilla Do, Jessica Hulitt, Sagar B. Kudchodkar, Alexandria P. Cogdill, Saar Gill, David L. Porter, Jennifer A. Woyach, Meixiao Long, Amy J. Johnson, Kami J. Maddocks, Natarajan Muthusamy, Bruce L. Levine, Carl H. June, John C. Byrd, Marcela V. Maus - Blood 2016 cited by 461

  11. Ibrutinib treatment improves T cell number and function in CLL patients

    Authors: Meixiao Long, Kyle A. Beckwith, Priscilla Do, Bethany L. Mundy-Bosse, Amber Gordon, Amy M. Lehman, Kami J. Maddocks, Carolyn Cheney, Jeffrey A. Jones, Joseph M. Flynn, Leslie A. Andritsos, Farrukh T. Awan, Joseph A. Fraietta, Carl H. June, Marcela V. Maus, Jennifer A. Woyach, Michael A. Caligiuri, Amy J. Johnson, Natarajan Muthusamy, John C. Byrd - Journal of Clinical Investigation 2017 cited by 377

  12. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

    Authors: Alan G. Ramsay, Amy J. Johnson, Abigail M. Lee, Güllü Görgün, Rifca Le Dieu, William Blum, John C. Byrd, John G. Gribben - Journal of Clinical Investigation 2008 cited by 594

  13. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

    Authors: Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A. Jones, Joseph M. Flynn, Leslie A. Andritsos, Kami J. Maddocks, Samantha Jaglowski, Kristie A. Blum, John C. Byrd, Jason A. Dubovsky, Amy J. Johnson - Blood 2015 cited by 174

  14. The B-cell receptor signaling pathway as a therapeutic target in CLL

    Authors: Jennifer A. Woyach, Amy J. Johnson, John C. Byrd - Blood 2012 cited by 409

  15. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

    Authors: John C. Byrd, Richard R. Furman, Steven Coutré, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O’Brien - Blood 2015 cited by 656

  16. Low abundance of the matrix arm of complex I in mitochondria predicts longevity in mice

    Authors: Satomi Miwa, Howsun Jow, Karen Baty, Amy J. Johnson, Rafal Czapiewski, Gabriele Saretzki, Achim Treumann, Thomas von Zglinicki - Nature Communications 2014 cited by 214

  17. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

    Authors: Sean D. Reiff, Rose Mantel, Lisa L. Smith, J.T. Greene, Elizabeth M. Muhowski, Catherine A. Fabian, Virginia M. Goettl, Minh Tran, Bonnie K. Harrington, Kerry A. Rogers, Farrukh T. Awan, Kami J. Maddocks, Leslie A. Andritsos, Amy M. Lehman, Deepa Sampath, Rosa Lapalombella, Sudharshan Eathiraj, Giovanni Abbadessa, Brian Schwartz, Amy J. Johnson, John C. Byrd, Jennifer A. Woyach - Cancer Discovery 2018 cited by 170

  18. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

    Authors: Brian J. Lannutti, Sarah Meadows, Sarah E. M. Herman, Adam Kashishian, Bart Steiner, Amy J. Johnson, John C. Byrd, Jeffrey Tyner, Marc Loriaux, Mike Deininger, Brian Druker, Kamal D. Puri, Roger G. Ulrich, Neill A. Giese - Blood 2010 cited by 718

  19. Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

    Authors: David Chiron, Maurizio Di Liberto, Peter Martin, Xiangao Huang, Jeff P. Sharman, Pedro Blecua, Susan Mathew, Priyanka Vijay, Ken Eng, Siraj M. Ali, Amy J. Johnson, Betty Chang, Scott Ely, Olivier Elemento, Christopher E. Mason, John P. Leonard, Selina Chen‐Kiang - Cancer Discovery 2014 cited by 272

  20. Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

    Authors: Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert, Matthew Stefanovski, Virginia M. Goettl, Kelly A. Smucker, Lisa L. Smith, Jason A. Dubovsky, William H. Towns, Jessica MacMurray, Bonnie K. Harrington, Melanie E. Davis, Stefania Gobessi, Luca Laurenti, Betty Chang, Joseph J. Buggy, Dimitar G. Efremov, John C. Byrd, Amy J. Johnson - Blood 2013 cited by 219

  21. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

    Authors: Rosa Lapalombella, Qingxiang Sun, Katie Williams, Larissa Tangeman, Shruti Jha, Yiming Zhong, Virginia M. Goettl, Emilia Mahoney, Caroline Berglund, Sneha Gupta, Alicia Farmer, Rajeswaran Mani, Amy J. Johnson, David Lucas, Xiaokui Mo, Dirk Daelemans, Vincent Sandanayaka, Sharon Shechter, Dilara McCauley, Sharon Shacham, Michael Kauffman, Yuh Min Chook, John C. Byrd - Blood 2012 cited by 297

  22. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

    Authors: Susan O’Brien, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd - Blood 2018 cited by 387

  23. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling

    Authors: Yuh-Ying Yeh, Hatice Gülçin Özer, Amy M. Lehman, Kami J. Maddocks, Lianbo Yu, Amy J. Johnson, John C. Byrd - Blood 2015 cited by 159

  24. Genetic heterogeneity of diffuse large B-cell lymphoma

    Authors: Jenny Zhang, Vladimir Grubor, Cassandra Love, Anjishnu Banerjee, Kristy L. Richards, Piotr A. Mieczkowski, Cherie H. Dunphy, William Choi, Wing Y. Au, Gopesh Srivastava, Patricia Lugar, David A. Rizzieri, Anand S. Lagoo, Leon Bernal‐Mizrachi, Karen P. Mann, Christopher R. Flowers, Kikkeri N. Naresh, Andrew M. Evens, Leo I. Gordon, Magdalena Czader, Javed Gill, Eric D. Hsi, Qingquan Liu, Alice C. Fan, Katherine H. Walsh, Dereje D. Jima, Lisa L. Smith, Amy J. Johnson, John C. Byrd, Micah A. Luftig, Ting Ni, Jun Zhu, Amy Chadburn, Shawn Levy, David B. Dunson, Sandeep S. Davé - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 534